• Link to X
  • Link to Facebook
  • Link to Instagram
  • Link to LinkedIn
  • Link to Youtube
  • Donate to fight Lafora disease!
  • Contact Us
info@chelseashope.org
Chelsea's Hope Lafora Children Research Fund
  • What is Lafora Disease?
    • About Lafora Disease
    • ICD-10 Codes for Lafora Disease
    • Lafora Disease Symptom Checker
    • Lafora Disease Therapy
    • Lafora Disease Clinical Pipeline Progress
    • ION283 Safety Study
    • Family Stories
  • About Us
    • Chelsea’s Story
    • Our Team
    • Advisory Board
    • Contact
  • News
  • Resources
    • For Families & Caregivers
      • Newly Diagnosed
      • Tips for Lafora Disease Families
      • Bereavement Support
      • G-Tube Tips – A Mother’s Perspective
      • Lafora Clinical Network Registry
      • Refer Your Clinician to the Registry
    • For Researchers
      • Lafora Mutations Database
      • Lafora Canine Registry and Database
      • Apply to Join the Clinical Registry
  • Events
    • 2026 Lafora Science Symposium
    • Courage in Care: Lafora Caregiver Series
    • Lafora Disease Roundtables
  • Get Involved
    • Ways to Give
    • Volunteer
    • Join Canine Registry
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

Elpida Therapeutics’ Press Release

August 4, 2026/by Chelsea's Hope

Elpida Therapeutics released a press release about acquiring ION283 and advancing this potential therapy. We are fortunate that Terry shared a letter with us earlier in the week.

For more information about the nonprofit biotech company and the license transfer from Ionis, you can read the press release that Elpida Therapeutics sent out here.

Read Press Release

Please direct any questions about ION283, Elpida Therapeutics, or the Safety Study to ion283@chelseashope.org.

Share this entry
  • Share on Facebook
  • Share on X
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail
https://chelseashope.org/wp-content/uploads/2022/02/ChelseasHope1.png 0 0 Chelsea's Hope https://chelseashope.org/wp-content/uploads/2022/02/ChelseasHope1.png Chelsea's Hope2026-08-04 12:45:052026-08-06 12:45:40Elpida Therapeutics’ Press Release
You might also like
Blog post G-Tube Tips for Lafora families G-Tube Tips – A Mother’s Perspective
ION283 Safety Study Approval ASO Therapy for Lafora Disease ION283 Safety Study Approved
IONIS Statement for the Lafora Community September 4, 2024 Ionis Statement for the Lafora Community
Text says 'ION283 Safety Study ASO Therapy for Lafora Disease' over a background image of the Dallas, Texas, skyline ION283 Safety Study on ClincialTrials.Gov
BECAUSE WE HAVE HOPE Lafora Holiday Season Auction 2024 Announcing Holiday Season Auction
Text says 'ION283 Safety Study ASO Therapy for Lafora Disease' over a background image of the Dallas, Texas, skyline Now Recruiting: ION283 Safety Study
ION238 Safety Study Update February 2025 Safety Study Update – February 2025
Town hall To discuss fundraising efforts and plan as a community. FULLY FUND THE SAFETY STUDY21 MAY 2025 WEDNESDAY Southwestern William P Clements Jr. U Register online to attend the Zoom meeting. Announcing a Town Hall: Fully Funding the Safety Study

About Chelsea’s Hope

Chelsea’s Hope began as a website in the fall of 2007 to share Chelsea Gerber’s story with family and friends. A 501(c)(3) organization since 2009, we have made an impact by raising awareness, connecting families worldwide, funding research, and maintaining hope.

Our mission is to improve the lives of those affected by Lafora disease and help accelerate the development of treatments. [Read More]

View Chelsea’s Hope Newsletter Archive 

Donate to Lafora Research

Latest News

  • Apply to Join the 2027 Board of Directors!

  • Press Release: United Against Lafora, Families Worldwide Raise Awareness

  • New Resource: Lafora Anti-Seizure Medication Guidelines

  • Join in Lafora Body Disease Day 2026!

  • Lafora Therapy Q&A Resources

  • Student Ambassador Applications Open

  • Social Security Added Lafora to Compassionate Allowances List

  • Elpida Therapeutics’ Press Release

  • ION283 to be Developed by Elpida Therapeutics

  • Update on the ION283 Program from Telethon

The mission of Chelsea’s Hope is to improve the lives of those affected by Lafora disease and help accelerate the development of treatments.

Chelsea’s Hope Lafora Children Research Fund is an IRS 501(c)3 nonprofit organization. EIN: 27-1008382

Location imageChelsea’s Hope c/o Dr. Donohue

976 Maywick Dr.

Lexington, KY 40504

info@chelseashope.org

Use ICD-10 code G40.C for Lafora.

    • Follow us on
    • Facebook
    • Instagram
    • Twitter
    • LinkedIn
    • YouTube
    • TikTok
ION283 Safety Study
Copyright © 2017-2026 Chelsea's Hope Lafora Children Research Fund. All Rights Reserved.
  • Home
  • News
  • About Lafora Disease
  • Donate
  • Contact
  • Privacy Policy – Other Policies
Link to: ION283 to be Developed by Elpida Therapeutics Link to: ION283 to be Developed by Elpida Therapeutics ION283 to be Developed by Elpida TherapeuticsAugust 3, 2026 Letter from Terry Elpida Therapeutics Link to: Social Security Added Lafora to Compassionate Allowances List Link to: Social Security Added Lafora to Compassionate Allowances List text says "social security" on a piece of paper in a typewriterSocial Security Added Lafora to Compassionate Allowances List
Scroll to top Scroll to top Scroll to top